

New Medicines Decisions for March 2025

ripretinib (Qinlock®)				
SMC Drug ID	Conditions	Decision	Date published on SMC Website	Date of decision / Expected date of decision
SMC2722	for the treatment of adult patients with advanced gastrointestinal stromal tumour (GIST) who have received prior treatment with three or more kinase inhibitors, including imatinib.	Not routinely available as not recommended for use in NHS Scotland	10/03/2025	26/02/2025
Other Decision Specified :				
Web Link : https://scottishmedicines.org.uk/media/9017/ripretinib-tablets-qinlock-final-feb-2025-for-website.pdf				
spesolimab (Spevigo®)				
SMC Drug ID	Conditions	Decision	Date published on SMC Website	Date of decision / Expected date of decision
SMC2729	for the treatment of flares in adult patients with generalised pustular psoriasis (GPP) as monotherapy.	Not routinely available as not recommended for use in NHS Scotland	10/03/2025	26/02/2025
Other Decision Specified :				
Web Link : https://scottishmedicines.org.uk/media/9018/spesolimab-spevigo-final-feb-2025-for-website.pdf				

New Medicines Decisions for March 2025

talazoparib (Talzenna®)				
SMC Drug ID	Conditions	Decision	Date published on SMC Website	Date of decision / Expected date of decision
SMC2753	In combination with enzalutamide for the treatment of adult patients with metastatic castration-resistant prostate cancer (mCRPC) in whom chemotherapy is not clinically indicated.	Available in line with local or regional guidance	10/03/2025	08/08/2025
Other Decision Specified :				
Web Link : https://scottishmedicines.org.uk/media/9019/talazoparib-talzenna-abb-final-feb-2025-for-website.pdf				
cabozantinib (Cabozantinib Ipsen)				
SMC Drug ID	Conditions	Decision	Date published on SMC Website	Date of decision / Expected date of decision
SMC2754	as monotherapy for the treatment of hepatocellular carcinoma (HCC) in adults who have previously been treated with sorafenib.	Not routinely available as the ADTC is waiting for further advice from local clinical experts	10/03/2025	02/05/2025
Other Decision Specified :				
Web Link : https://scottishmedicines.org.uk/media/9016/cabozantinib-cabozantinib-ipsen-abb-final-feb-2025-for-website.pdf				

amivantamab (Rybrevant®)				
SMC Drug ID	Conditions	Decision	Date published on SMC Website	Date of decision / Expected date of decision
SMC2768	in combination with carboplatin and pemetrexed for the treatment of adult patients with advanced non-small cell lung cancer (NSCLC) with EGFR Exon 19 deletions or Exon 21 L858R substitution mutations after failure of prior therapy including an EGFR tyrosine kinase inhibitor (TKI).	Not routinely available as not recommended for use in NHS Scotland	10/03/2025	26/02/2025
Other Decision Specified : Non-submission				
Web Link : https://scottishmedicines.org.uk/media/9020/amivantamab-rybrevant-non-sub-final-feb-2025-for-website.pdf				
atezolizumab (Tecentriq®)				
SMC Drug ID	Conditions	Decision	Date published on SMC Website	Date of decision / Expected date of decision
SMC2769	as monotherapy for the first-line treatment of adult patients with advanced NSCLC who are ineligible for platinum-based therapy.	Not routinely available as not recommended for use in NHS Scotland	10/03/2025	26/02/2025
Other Decision Specified : Non-submission				
Web Link : https://scottishmedicines.org.uk/media/9021/atezolizumab-tecentriq-non-sub-final-feb-2025-for-website.pdf				